Sanjiv Modi

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology · 2009 · 272 citations

Medicine, Pharmacology, Pharmacotherapy +17

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

Sonali M. Smith, Koen van Besien, Theodore Karrison et al. · Journal of Clinical Oncology · 2010 · 208 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

Walter M. Stadler, David J. Vaughn, Guru Sonpavde et al. · Cancer · 2013 · 106 citations

Medicine, Oncology, Pharmacology +10

Interferon-Dependent Activation of the Serine Kinase PI 3′-Kinase Requires Engagement of the IRS Pathway but Not the Stat Pathway

Shahab Uddin, Beata Majchrzak, Pu-Chen Wang et al. · Biochemical and Biophysical Research Communications · 2000 · 71 citations

Life Sciences, Biochemistry, Molecular Biology +15

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium

Manish Sharma, Kristen Wroblewski, Blasé N. Polite et al. · Investigational New Drugs · 2011 · 48 citations

Medicine, Oncology, Pharmacology +10